Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation

Artificial Cells, Nanomedicine and Biotechnology

Volumn 45, Issue 7, 2017, Pages 1397-1407

  Pandit, Jayamanti ^a   Sultana, Yasmin ^a   Aqil, Mohd ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

bevacizumab; Box Behnken statistical design; Chitosan; nanoparticles; posterior eye diseases

Indexed keywords

CHITOSAN; CONTROLLED DRUG DELIVERY; EMULSIFICATION; ENDOTHELIAL CELLS; NANOPARTICLES; PARTICLE SIZE; POLYDISPERSITY;

BEVACIZUMAB; CHORIO-ALLANTOIC MEMBRANES; DOUBLE EMULSION-SOLVENT EVAPORATION; EYE DISEASE; POLY (VINYL ALCOHOL) (PVA); POLYDISPERSITY INDICES; STATISTICAL DESIGN; VASCULAR ENDOTHELIAL GROWTH FACTOR;

TARGETED DRUG DELIVERY;

BEVACIZUMAB; CHITOSAN; NANOPARTICLE; POLYGLACTIN; POLYVINYL ALCOHOL; WATER OIL CREAM; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ARTICLE; CHORIOALLANTOIC MEMBRANE ASSAY; CHORIOALLANTOIS; CONTROLLED STUDY; DEACETYLATION; DISPERSITY; DRUG RELEASE; GOAT; HYPEREMIA; IN VITRO STUDY; MUCOADHESION; NONHUMAN; PARTICLE SIZE; RETINA; RETINA HEMORRHAGE; SCLERA; ZETA POTENTIAL; ADHESION; ANIMAL; CHEMISTRY; CHICKEN; MATERIALS TESTING; METABOLISM; MUCOSA; PERMEABILITY; PIG;

ADHESIVENESS; ANIMALS; BEVACIZUMAB; CHICKENS; CHITOSAN; DRUG CARRIERS; DRUG LIBERATION; LACTIC ACID; MATERIALS TESTING; MUCOUS MEMBRANE; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYGLYCOLIC ACID; RETINA; SWINE;

EID: 84995666078     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.1080/21691401.2016.1243545     Document Type: Article

References (58)

1. Ameeduzzafar Ali J, Bhatnagar A, Kumar N, Ali A., 2014. Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. Int J Biol Macromol. 65:479–491.
2. Amrite AC, Edelhauser HF, Kompella UB., 2008. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 49:320–322.
3. Badawi AA, El-Laithy HM, El-Qidra RK, El-Mofty H., 2008. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 31:1040–1049.
4. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ., 2007. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114:855–859.
5. Basaran E, Yazan Y., 2012. Ocular application of chitosan. Expert Opin Drug Deliv. 9:701–712.
6. Cheung N, Mitchell P, Wong TY., 2010. Diabetic retinopathy. Lancet. 376:124–136.
7. de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ., 2010. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 62:100–117.
8. de la Fuente M, Seijo B, Alonso MJ., 2008. Bioadhesive hyaluronan–chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther. 15:668–676.
9. del Amo EM, Urtti A., 2008. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 13:135–143.
10. Durán-Lobato M, Muñoz-Rubio I, Holgado M, Álvarez-Fuentes J, Fernández-Arévalo M, Martín-Banderas L., 2014. Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotech. 10:1068–1079.
11. Felt O, Carrel A, Baehni P, Buri P, Gurny R., 2000. Chitosan as tear substitute: a wetting agent endowed with antimicrobial efficacy. J Ocul Pharmacol Ther. 16:261–270.
12. Ferrara N, Gerber HP, LeCouter J., 2003. The biology of VEGF and its receptors. Nat Med. 9:669–676.
13. Fung AE, Rosenfeld PJ, Reichel E., 2006. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 90:1344–1349.
14. Gambrelle J, Kodjikian L, Abi-Ayad N, Wolff B, Grange JD., 2006. Grange, persistent unsealed sclerotomy after intravitreal injection of triamcinolone acetonide with a 30-gauge needle. J Fr Ophtalmol. 29:e22.
15. Gan Q, Wang T, Cochrane C, McCarron P., 2005. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 44:65–73.
16. Gan Q, Wang T., 2007. Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces. 59:24–34.
17. Guo C, Gemeinhart RA., 2008. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur J Pharm Biopharm. 70:597–604.
18. Hosoya KI, Lee VH, Kim KJ., 2005. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm. 60:227–240.
19. Huang D, Wang L, Dong Y, Pan X, Li G, Wu C., 2014. A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles. Eur J Pharm Biopharm. 88:104–115.
20. ICCVAM. Appendix B3 of “ICCVAM test method evaluation report: current validation status of in vitro test methods proposed for identifying eye injury hazard potential of chemicals and products” NIH Publication, 2010. Available from: http://iccvam.niehs.nih.gov/methods/ocutox/MildMod-TMER.htm
21. Jain GK, Pathan SA, Akhter S, Ahmad N, Jain N, Talegaonkar S, Khar RK, Ahmad FJ., 2010. Mechanistic study of hydrolytic erosion and drug release behaviour of PLGA nanoparticles: influence of chitosan. Polym Degrad Stab. 95:2360–2366.
22. Jain GK, Pathan SA, Akhter S, Jayabalan N, Talegaonkar S, Khar RK, Ahmad FJ., 2011. Microscopic and spectroscopic evaluation of novel PLGA-chitosan nanoplexes as an ocular delivery system. Colloids Surf B Biointerfaces. 82:397–403.
23. Katiyar S, Pandit J, Mondal RS, Mishra AK, Chuttani K, Aqil M, Ali A, Sultana Y., 2014. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym. 102:117–124.
24. Kaur IP, Smitha R., 2002. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 28:353–369.
25. Kawashima T, Nagai N, Kaji H, Kumasaka N, Onami H, Ishikawa Y, et al. 2011. A scalable controlled-release device for transscleral drug delivery to the retina. Biomaterials. 32:1950–1956.
26. Kesavan K, Kant S, Singh PN, Pandit JK., 2012. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation. Current Eye Res. 38:342–352.
27. Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, Csaky KG., 2004. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 45:2722–2731.
28. Kim WJ, Jeong HO, Chung SK., 2010. The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol. 24:230–236.
29. Lamoureux EL, Wong TY., 2011. Diabetic retinopathy in 2011: further insights from new epidemiological studies and clinical trials. Diabetes Care. 34:1066–1067.
30. Lamprecht A, Ubrich N, Pérez MH, Lehr CM, Hoffman M, Maincent P., 2000. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm. 196:177–182.
31. Lu Y, Zhou N, Huang X, Cheng JW, Li FQ, Wei RL, Cai JP., 2014. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophthalmol. 7:1–7.
32. Mainardes RM, Evangelista RC., 2005. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 290:137–144.
33. Misra GP, Singh RS, Aleman TS, Jacobson SG, Gardner TW, Lowe TL., 2009. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials. 30:6541–6547.
34. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M., 2010. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 51:1606–1608.
35. Molokhia SA, Sant H, Simonis J, Bishop CJ, Burr RM, Gale BK, Ambati BK., 2010. The capsule drug device: novel approach for drug delivery to the eye. Vision Res. 50:680–685.
36. Moon JW, Song YK, Jee JP, Kim CK, Choung HK, Hwang JM., 2006. Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Invest Ophthalmol Vis Sci. 47:3968–3974.
37. Myers RH, Montgomery DC., Response Surface Methodology Process and Product Optimization Using Designed Experiments. 2nd ed. New York: John Wiley & Sons, Inc.; 2002.
38. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM., 2007. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 3:173–183.
39. Oh JY, Kim MK, Wee WR., 2009. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea. 28:1070–1073.
40. Pandit J, Sultana Y, Aqil M., 2014. Poly(lactide-co-glycolide) nanoparticles for an extended delivery of bevacizumab to retina: formulation and in vitro characterization. Adv Sci Lett. 20:1588–1593.
41. Pascolini D, Mariotti SP., 2012. Global estimates of visual impairment: 2010. Br J Ophthalmol. 96:614–618.
42. Ranta VP, Mannermaa E, Lummepuro K, Subrizi A, Laukkanen A, Antopolsky M, et al. 2010. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 148:42–48.
43. Ranta VP, Urtti A., 2006. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 58:1164–1181.
44. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Jr, et al. 2006. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 26:495–511.
45. Shmueli RB, Ohnaka M, Miki A, Pandey NB, de Silva RL, Koskimaki JE, et al. 2013. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials. 34:7544–7551.
46. Simó R, Sundstrom JM, Antonetti DA., 2014. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 37:893–899.
47. Son S, Lee WR, Joung YK, Kwon MH, Kim YS, Park KD., 2009. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int J Pharm. 368:178–185.
48. Srikantha N, Mourad F, Suhling K, Elsaid N, Levitt J, Chung PH, Jackson TL., 2012. Influence of molecular shape, conformability, net surface charge, and tissue interaction on transscleral macromolecular diffusion. Exp. Eye Res. 102:85–92.
49. Tavaszi J, Budai P., 2006. The use of HET-CAM test in detecting the ocular irritation. Commun Agric Appl Biol Sci. 72:137–141.
50. Tyagi P, Barros M, Stansbury JW, Kompella UB., 2013. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 10:2858–2867.
51. van Wijngaarden P, Coster DJ, Williams KA., 2005. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 293:1509–1513.
52. Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, Khoshayand MR, Atyabi F, Sabzevari A, Esfahani MR, Dinarvand R., 2013. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci. 50:341–352.
53. Wang Y, Li P, Kong L., 2013. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech. 14:585–592.
54. Watson PG, Young RD., 2004. Scleral structure, organisation and disease. A review. Exp Eye Res. 78:609–623.
55. Wen H, Hao J, Li SK., 2013. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab. J Pharm Sci. 102:892–903.
56. ® from polysaccharides cross-linked hydrogels for ocular drug delivery. Int J Biol Macromol. 60:272–276.
57. Yoncheva K, Vandervoort J, Ludwig A., 2009. Influence of chitosan layer on the properties of surface modified poly(lactide-co-glycolide) nanoparticles. J Disper Sci Technol. 30:213–216.
58. Yu J, Xu X, Yao F, Luo Z, Jin L, Xie B, et al. 2014. In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications. Int J Pharm. 470:151–157.